lercanidipine has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bombelli, M; Brambilla, G; Casati, A; Cuspidi, C; Grassi, G; Mancia, G; Pizzalla, DP; Riva, M; Seravalle, G | 1 |
| Aguilar, A; Angulo, E; Canelada, JA; Cidoncha, F; Díaz Olea, E; Fuentes, J; Garrido, J; Guerras, M; Hidalgo, P; Iglesias, M; Lapie, J; López Acedo, A; Peña, J; Robles, NR | 1 |
2 trial(s) available for lercanidipine and Obesity
| Article | Year |
|---|---|
Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Enalapril; Felodipine; Female; Heart Rate; Humans; Hypertension; Insulin Resistance; Male; Metabolome; Middle Aged; Norepinephrine; Obesity; Random Allocation; Sympathetic Nervous System | 2016 |
[Evaluation of lercanidipine in the general practice setting].
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Cholesterol; Diabetes Complications; Dihydropyridines; Family Practice; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Obesity; Treatment Outcome; Uric Acid | 2003 |